-

Sensus Healthcare to Participate in the 37th Annual ROTH Conference

BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces it will be participating in Roth Capital’s 37th Annual ROTH Conference, being held March 17-18 in Dana Point, California. Management will be holding one-on-one meetings with registered investors during the conference.

Registered attendees who would like to schedule a meeting with Sensus Healthcare management should contact their ROTH representative or Tirth Patel at tpatel@allianceadvisors.com.

About Sensus Healthcare

Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.

Contacts

Alliance Advisors IR
Tirth T. Patel
tpatel@allianceadvisors.com
212-201-6614

Sensus Healthcare, Inc.

NASDAQ:SRTS

Release Versions

Contacts

Alliance Advisors IR
Tirth T. Patel
tpatel@allianceadvisors.com
212-201-6614

More News From Sensus Healthcare, Inc.

Sensus Healthcare Expands Role of President Michael Sardano to Include Chief Commercial Officer

BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced that President Michael Sardano has been appointed to the additional role of Chief Commercial Officer. In this newly created position, Mr. Sardano will direct the company’s global sales, marketing and commercial strategy across its po...

Sensus Healthcare Appoints Eric Sachetta to its Board of Directors

BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Eric Sachetta to the Company’s Board of Directors. Mr. Sachetta is filling the vacancy that resulted from the passing of long-serving Director Bill McCall. Throughout his career, Mr. Sachetta has held a range of le...

Sensus Healthcare Reports Third Quarter 2025 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and nine months ended September 30, 2025. Highlights of the third quarter of 2025 and subsequent weeks include the following: CMS established coding validating SRT for treating non-melanoma skin cancer Revenu...
Back to Newsroom